05.11.16

Alimera Sciences’ Iluvien Data Presented at SFO 2016

Source: Alimera Sciences

Alimera Sciences announced that data from six Iluvien post-marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10, according to a company news release.

The six Alimera data presentations at SFO were as follows:

  • Results in Real Life of the Fluocinolone Acetonide Implant, interim Analysis at 1 Year of the European Registries Compared to the Phase 3 Study FAME, authored by Corinne Dot, Military hospital Desgenettes, Lyon.
  • Multicenter Prospective Study to Evaluate the Efficacy and Tolerance of Fluocinolone Acetonide 0.2 mg for Chronic Diabetic Macular Edema, authored by J. Nascimento, Lisbon, Portugal.
  • The Efficacy of Fluocinolone Acetonide 0.2 mg in Diabetic Macular Oedema with Vitrectomised Patients, authored by Ali Erginay, University hospital of Lariboisiere, Paris.
  • Methodologies in the Treatment of DMO, authored by M. Weber, University hospital of Nantes, R. Tadayoni, University hospital of Lariboisiere, Paris, and J.F. Korobelnik, University hospital of Bordeaux.
  • Management of Steroid Induced IOP Rise in Diabetics IOP, authored by Phillippe Denis, University hospital of Lyon, and J.P. Nordmann, XV-XX hospital, Paris.
  • Impact of Associated Therapies in FAME Chronic Diabetic Macular Edema, authored by P. Labelette, University hospital of Lille, and F. Fajnkuchen, University hospital of Bobigny.

Related Content